Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity.
The usefulness of pretreatment biochemical parameters in the prediction of nephrotoxicity associated with cisplatin treatment was studied. Twenty-two patients, who received 29 cycles of cisplatin, were evaluated. Cisplatin was given every 3-4 weeks with saline and mannitol. Azotemia occurred in almost all patients and was transient, peaking 1-2 weeks after therapy. The change in serum creatinine from baseline to peak correlated inversely with pretreatment serum albumin (r = -0.73; P less than 0.01) and with pretreatment uric acid (r = 0.76; P less than 0.01). Ten patients with uric acid levels of less than 6 mg/dl were receiving allopurinol. The competition between organic anions and cisplatin for excretion may, in part, explain the protective effects of hypouricemia. Hypoalbuminemia affects peritubular oncotic pressure and may in turn affect platinum excretion. Hypoalbuminemia also reduces the half-life of cisplatin, exposing the kidney to more of the unbound filterable drug.
D002945:Cisplatin / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D006801:Humans; D007019:Hypoproteinemia / Q000150:complications*; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced*; D012709:Serum Albumin / Q000172:deficiency*; D014527:Uric Acid / Q000097:blood*
D012709:Serum Albumin; D014527:Uric Acid; D003404:Creatinine; D002945:Cisplatin